ArticleMetabolomics : Official journal of the Metabolomic Society2025
Corroborated evidence on change of metabolome after ischemic stroke due to large vessel occlusion.
Article in Metabolomics : Official journal of the Metabolomic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Advances in genetics and multi-omics for ischemic stroke: from pathogenesis to clinical translation.Frontiers in genetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionMetabolomic studies which search for acute ischemic stroke (AIS) biomarkers commonly have contradictory findings. Robust methodology is required to understand true metabolome changes after AIS.
methodsTo improve validity, we obtained corroborative evidence on change of serum metabolome after AIS by: (1) focusing on patients with large vessel occlusion (LVO), (2) combining cross-sectional and longitudinal study designs, and (3) performing analysis using different metabolome platforms: Nuclear Magnetic Resonance (NMR) and Liquid Chromatography-Mass Spectrometry (LC-MS). In the cross-sectional part we compared serum metabolome of 84 AIS patients and 82 controls using NMR at 48-72 h, while in the longitudinal part we prospectively analyzed serum metabolome using LC-MS on 15 AIS patients at < 24 h, 48-72 h, 5-7 days, 80-120 days. We hypothesized that serum metabolites elevated in cross-sectional part would show rising trajectory in longitudinal part, and vice versa.
resultsWe found that glycerol, phosphatidylethanolamine (PE), ceramide, phenylalanine and their derivatives had consistent increases, while other key metabolites including histidine, tyrosine, valine, glutamine, phosphatidylcholine (PC), sphingomyelin, fatty acids (FA) had consistent decreases after AIS.
conclusionWe identified corroborated changes in metabolome after AIS across different technologies and study designs. These changes correspond to loss of nerve cell membrane integrity and activation of alternative metabolic pathways in the setting of blood brain barrier (BBB) disruption. If proven on a larger sample, our findings may improve prediction of mortality, and functional outcomes after AIS.
Indexed as
Identifiers
40123037What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.